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Objectives This study sought to evaluate the use of a continuous-flow rotary left ventricular assist device (LVAD) as a bridge
to heart transplantation.
Background LVAD therapy is an established treatment modality for patients with advanced heart failure. Pulsatile LVADs
have limitations in design precluding their use for extended support. Continuous-flow rotary LVADs represent an
innovative design with potential for small size and greater reliability by simplification of the pumping mechanism.
Methods In a prospective, multicenter study, 281 patients urgently listed (United Network of Organ Sharing status 1A or
1B) for heart transplantation underwent implantation of a continuous-flow LVAD. Survival and transplantation
rates were assessed at 18 months. Patients were assessed for adverse events throughout the study and for
quality of life, functional status, and organ function for 6 months.
Results Of 281 patients, 222 (79%) underwent transplantation, LVAD removal for cardiac recovery, or had ongoing LVAD
support at 18-month follow-up. Actuarial survival on support was 72% (95% confidence interval: 65% to 79%) at
18 months. At 6 months, there were significant improvements in functional status and 6-min walk test (from 0%
to 83% of patients in New York Heart Association functional class I or II and from 13% to 89% of patients com-
pleting a 6-min walk test) and in quality of life (mean values improved 41% with Minnesota Living With Heart
Failure and 75% with Kansas City Cardiomyopathy questionnaires). Major adverse events included bleeding,
stroke, right heart failure, and percutaneous lead infection. Pump thrombosis occurred in 4 patients.
Conclusions A continuous-flow LVAD provides effective hemodynamic support for at least 18 months in patients awaiting
transplantation, with improved functional status and quality of life. (Thoratec HeartMate II Left Ventricular Assist
System [LVAS] for Bridge to Cardiac Transplantation; NCT00121472) (J Am Coll Cardiol 2009;54:312–21)
© 2009 by the American College of Cardiology Foundation
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July 21, 2009:312–21 Continuous-Flow LVAD2) or as permanent support as an alternative to transplantation
3,4). Historically, patients have been supported by devices
ngineered with pulsatile design (i.e., HeartMate IP1000, VE,
r XVE, Thoratec PVAD or IVAD, Thoratec Corporation,
leasanton, California; or Novacor, World Heart Corporation,
akland, California) (2,5–8). These devices are designed with
n internal pumping chamber and inflow and outflow valves
ermitting cyclic filling and emptying with pump actuation
licited by either pneumatic or electrical systems (9). Previous
tudies have demonstrated the efficacy of these devices with
egard to improvement in survival to transplantation (2)
nd improvement in survival compared with optimal
edical management for patients with advanced heart
ailure, not candidates for transplantation (3).
See page 322
Pulsatile devices have limitations in their design that
reclude their practical use for extended mechanical circu-
atory support (MCS). These limitations include a large
ump size, requirement for extensive surgical dissection for
mplant, a large body habitus of the recipient, the presence
f a large-diameter percutaneous lead for venting air, and
udible pump operation (2,7). A critical limitation of the
ajority of these devices has been the high incidence of
eoperation for device exchange for device infection or
alfunction (3,10–12).
The REMATCH (Randomized Evaluation of Mechan-
cal Assistance for the Treatment of Congestive Heart
ailure) trial demonstrated a survival advantage for LVAD
herapy over optimal medical management for patients
ith advanced heart failure who were not eligible for
ransplantation. Although demonstrating the potential of
CS in providing improved survival, this trial demon-
trated the risk of mechanical failure and device-related
omplications inherent in the pulsatile HeartMate VE
VAD (3,12). In patients surviving up to 2 years on
evice support, nearly 65% underwent replacement for
nfection or malfunction (12).
The development of continuous-flow rotary pump tech-
ology represents an innovative design for LVADs (13–18).
hese devices have the advantage of a smaller pump size and
otential for greater mechanical reliability by simplification
f the pumping mechanism (13,14). Reports from clinical
rials of these newer pump designs have demonstrated
fficacy in providing hemodynamic support and favorable
isk-to-benefit ratio (15–18).
The HeartMate II LVAD is a continuous-flow rotary
ump that has completed a U.S. Food and Drug Admin-
stration (FDA)-approved pivotal trial in 133 BTT patients
18). Since this report, 336 additional patients have under-
one implantation of the HeartMate II LVAD as of April
008 through a continued-access protocol approved by the
DA. We report on the first 281 patients entered into this mlinical evaluation who have
ompleted study end points or at
east 18-month follow-up after
VAD implantation.
ethods
tudy design. Patients were en-
olled in the study conducted at 33
enters in the U.S. between March
005 and April 2008 (18). The
tudy was supervised by the Tho-
atec Corporation. The clinical af-
airs and biostatistics departments
t Thoratec designed the trial in consultation with the FDA
nd clinical investigators. Coordinators at each site collected
tudy data, which was forwarded to the data analysis center of
he sponsor. The academic authors vouch for the completeness
nd accuracy of the data and the analyses. A data and safety
onitoring board, consisting of 4 independent physicians and
biostatistician who were not investigators in the study, met
outinely to review study compliance, adverse events, quality of
ife, and outcomes of patients. These 5 committee members
ere compensated for their time, but none have any financial
nterest in the Thoratec Corporation or stand to gain finan-
ially from the outcome of the trial. A clinical events commit-
ee of 4 independent physicians who were not involved in the
onduct of the trial reviewed, classified, and adjudicated the
auses of death and all adverse events. The study was con-
ucted in compliance with FDA regulations for Good Clinical
ractices. The protocol was approved by the FDA and the
nstitutional review board at each participating center.
tudy subjects. Patients with heart failure who were on a
aiting list for heart transplantation at each center were
ligible for study enrollment. Patients were required to have
ymptoms of New York Heart Association (NYHA) func-
ional class IV heart failure and to be ill enough to have high
riority for transplantation (United Network for Organ
haring status 1A or 1B). A complete list of study inclusion
nd exclusion criteria have been reported (18). All partici-
ating patients provided written informed consent before
nrolling in the study.
ata collection baseline assessment. Baseline data were
btained upon patient consent and enrollment into the
tudy. Information collected for baseline data have been
reviously reported (18).
ontinuous-flow pump. The continuous-flow LVAD
sed in this study was the HeartMate II LVAS (Thoratec
orporation), which is a rotary pump with axial flow design
Fig. 1) (18). The system design and operating performance
f the device have been previously described (18).
urgical implantation. Surgical implantation of the
eartMate II LVAS was conducted according to the Heart-
ate II LVAS “Instructions for Use.” Post-operative treat-
Abbreviations
and Acronyms
BTT  bridge-to-
transplantation
FDA  Food and Drug
Administration
LVAD  left ventricular
assist device
MCS  mechanical
circulatory support
NYHA  New York Heart
Associationent included initiation of an anticoagulation regimen (18).
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Continuous-Flow LVAD July 21, 2009:312–21ollow-up after device implantation. Post-operative
edical care was managed according to each investigator’s
sual practice. Details of the protocol for patient follow-up
fter device implantation have been previously reported
18). Readmissions to the hospital and adverse events were
ecorded throughout the study as they occurred with the use
f standardized definitions (18). All deaths of patients and
auses of death were determined at autopsy when possible,
xamination of medical records, or by interviews with family
Figure 1 Components of the Continuous-Flow LVAD
(A) The inflow cannula is inserted into the apex of the left ventricle, and the
outflow cannula is anastomosed to the ascending aorta. Blood exits through
the left ventricular apex and into the left ventricular assist device (LVAD),
which pumps throughout cardiac diastole and systole into the ascending aorta.
(B) The LVAD pump is placed within the abdominal wall or peritoneal cavity. A per-
cutaneous lead carries the electrical cable to an electronic controller and battery
packs, which are worn on a belt and shoulder holster, respectively.embers. Final adjudication was determined by the clinical mvents committee. Major device malfunctions were defined
s those resulting in death or requiring device replacement.
utcomes. The principal outcomes assessed through 18
onths after enrollment were the proportions of patients
ho had undergone transplantation, had undergone explan-
ation of the device because of recovery of ventricular
unction, or continued with ongoing MCS. The proportion
f patients who died on support and those who were
ithdrawn from the study were also followed for 18 months.
atients who had the original continuous-flow pump re-
laced with another identical device remained in the study,
hereas patients who had the original pump replaced with
different type of device were withdrawn from the study.
tatistical analysis. Differences between measures of con-
inuous variables before and after implantation were ana-
yzed by a paired t test. McNemar’s test was used for
omparisons between paired categorical variables. The level
f statistical significance was set at p  0.05. All statistical
omparisons were 2 sided. Biochemical and hemodynamic
ariables are presented as mean (SD), and median and
ange were used where appropriate. Discrete variables are
resented as percentages. Adverse events are presented both
s the percentage of patients who had the event and as event
ates per patient-year. Survival analysis for patients continu-
ng on mechanical support was performed with the Kaplan-
eier method. Patients were censored for transplantation,
ecovery of the natural heart, and withdrawal from the
tudy. The Kaplan-Meier method also was used for analysis
f freedom from death due to major device malfunction or
eed for device replacement for all causes.
esults
tudy patients. A total of 469 patients meeting study-
ntry criteria were enrolled into the study as of April 2008
nd underwent implantation of the continuous-flow LVAD
s a BTT. The initial 281 of the 469 patients that completed
tudy end points or have at least 18 months of follow-up
ith ongoing device support comprise the patients in this
eport. These 281 patients include additional follow-up of
he first 133 patients implanted as part of a primary cohort
nd previously reported (18). Most of the subjects were men
ith a median age of 54 years (Table 1). The most frequent
eart failure etiology was nonischemic cardiomyopathy. All
atients had symptoms of advanced heart failure despite
ptimal medical management with oral medications. The
ajority of patients in the study were receiving an intrave-
ous inotrope, with approximately one-third requiring 2
notropes. Patients not administered inotrope therapy were
ntolerant to it as the result of ventricular arrhythmias.
orty-five percent of patients were on concomitant support
ith an intra-aortic balloon pump. Previous biventricular
acing therapy failed in a significant proportion of these
atients. Pre-operative hemodynamic and laboratory assess-
ent were consistent with a group of patients with ad-
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ventricular stroke work index.
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July 21, 2009:312–21 Continuous-Flow LVADanced heart failure requiring inotrope and/or intra-aortic
alloon pump support.
utcomes. Of the 281 patients, 222 (79%) either received
transplant, recovered cardiac function and underwent
evice explantation, or remained alive with ongoing LVAD
upport at 18-month follow-up (Fig. 2). At 18 months, 157
55.8%) patients had received a heart transplant, 58 (20.6%)
emained alive with ongoing LVAD support, 56 (19.9%)
atients died, 7 (2.5%) patients recovered cardiac function
nd underwent device explantation, and 3 (1%) patients
ere withdrawn from the study after device explantation
nd exchange for another type of LVAD. The median time
o transplantation was 118 days (range 10 to 545 days),
edian time to death was 64 days (range 0 to 797 days), and
he median time to pump removal after cardiac recovery was
02 days (range 161 to 558 days). The median duration of
upport for all patients was 155 days (range 0 to 1,026 days),
ith a cumulative follow-up of 181 patient-years.
Overall survival for the patients who continued on LVAD
upport was 82% (95% confidence interval [CI]: 77% to 87%)
t 6 months, 73% (95% CI: 66% to 80%) at 1 year, and 72%
95% CI: 65% to 79%) at 18 months (Fig. 3). Of the 157
atients that received a transplant, post-transplant survival was
6% at 30 days and 86% at 1 year. As of June 2008, 42 patients
ere alive with device support with a median duration of 1.6
ears (longest duration 3.1 years). Of these patients, 71%
emained active on the transplant list, and 29% were not listed
Table 2). Only 3 patients were not listed for irreversible
edical conditions or degree of organ dysfunction.
Average LVAD estimated blood flow at 6 months of
upport was 5.6  0.9 l/min (flow index 2.83  0.45
/min/m2) at a pump speed of 9,467  499 rpm. Left
entricular end-diastolic dimension determined by echocar-
iography reduced from 69.7 12.3 mm at baseline to 59.2
5.1 mm at 1 week and 56.7  14.5 mm at 6 months.
nticoagulation with warfarin resulted in an average inter-
ational normalized ratio throughout support of 2.1  0.8
median 2.0). Twenty-five (8.9%) patients underwent trans-
lantation during their initial hospital stay, and 33 (11.7%)
atients died on LVAD support before discharge.
Two hundred twenty (78%) patients were discharged
rom the hospital with the LVAD, with a median hospital
tay after surgery of 25 days (range 8 to 180 days). The
edian number of days out of hospital before transplanta-
ion, readmission, or death was 55.5 (range 1 to 892 days).
ne hundred forty nine (68%) patients required rehospital-
zation after discharge, with a median duration of rehospi-
alization of 5 days (range 0 to 209 days).
auses of death. The primary causes of death were sepsis
n 11 patients (4%), stroke in 10 (4%; ischemic: n  5, 2%;
emorrhagic: n  5, 2%), and right heart failure in 7 (3%).
ther causes included device-related deaths in 7 patients
3%), multiorgan failure in 5 (2%), anoxic brain injury in 3
1%), bleeding in 3 (1%), and other causes in 10 (4%)aseline Characteristics of the 281 PatientsTable 1 Baseline Characteristics of the 281 Patients
Age (yrs) 50 13
Male 214 (76)
Caucasian/African American 194 (69)/61 (22)
Body mass index (kg/m2) 27.1 5.8
Body surface area (m2) 2.0 0.3
Ischemic etiology of heart failure 121 (43)
Left ventricular ejection fraction (%) 16.3 6.5
Arterial blood pressure (mm Hg)
Systolic 98.1 15.0
Diastolic 61.4 11.2
Pulmonary-capillary wedge pressure (mm Hg) 25.4 7.9
Cardiac index (l/min/m2) 2.1 0.6
Heart rate (beats/min) 92.2 18.8
Pulmonary artery pressure (mm Hg)
Systolic 51.4 13.7
Diastolic 26.8 8.4
Mean 35.9 9.6
Pulmonary vascular resistance (Wood Units) 2.8 1.4
Central venous pressure (mm Hg) 12.6 6.5
RVSWI (mm Hg·ml/m2) 548 291
NYHA functional class IV
Serum sodium (mmol/l) 133.7 5.2
Serum albumin (g/dl) 3.5 0.6
Pre-albumin (mg/dl) 18.4 7.6
Cholesterol (mg/dl) 129 41
Serum creatinine (mg/dl) 1.4 0.5
Estimated creatinine clearance (ml/min) 78.6 35.1
Blood urea nitrogen (mg/dl) 30.4 17.1
ALT (IU/l) 106 278
AST (IU/l) 92 281
Total bilirubin (mg/dl) 1.3 0.9
LDH (mg/dl) 584 1,489
Hematocrit (%) 34.8 5.5
White blood count (1,000)/ml 9.0 3.4
Platelets (1,000/ml) 223 88
International normalized ratio 1.3 0.5
Concomitant medications
Intravenous inotrope agents 252 (90)
Intolerant to inotropes due to arrhythmias 29 (10)
2 or more inotrope agents 91 (32)
Diuretics 228 (81)
ACE inhibitors 73 (26)
Angiotension-II receptor antagonists 17 (6)
Beta-blockers 100 (36)
Digoxin 111 (40)
Hydralazine 37 (13)
Amiodarone 105 (37)
Heparin 174 (62)
Warfarin 6 (2)
Aspirin 89 (32)
Cardiac resynchronization therapy 135 (48)
ICD 213 (76)
IABP 126 (45)
Mechanical ventilation 26 (9)
alues are expressed as mean  SD or n (%).
ACE angiotensin-converting enzyme; ALT serum alanine aminotransaminase; AST serum
spartate aminotransaminase; IABP intra-aortic balloon pump; ICD implantable cardioverter-cancer, respiratory failure, hyperthermia, air embolism, and
u
t
n
d
1
(
t
d
i
f
r
A
w
f
w
S
r
c
i
t
d
w
316 Pagani et al. JACC Vol. 54, No. 4, 2009
Continuous-Flow LVAD July 21, 2009:312–21nknown). There were a total of 7 device-related deaths, 4
hat were attributed to malfunction of implanted compo-
ents (pump thrombosis in 2, inflow graft that was twisted
uring implantation in 1, and outflow elbow disconnect in
) and 3 that were attributed to external components
severed percutaneous lead in 1, power loss in 2). Only 13 of
he deaths in the 281 (4.6%) patients (or 23% of the 56
eaths) occurred after 6 months of device support and
ncluded 5 from sepsis, 2 from power loss of the LVAD, 2
rom withdrawal of support, and 1 each from cancer,
espiratory failure, hemorrhage, and unknown.
Figure 2 Outcomes for 281 Patients After Implantation of the C
Competing outcomes analysis of patients undergoing implantation of the continuo
Figure 3 Kaplan-Meier Survival Analysis
Survival analysis for patients who continued to receive support with the continuou
ventricular assist device censored at the time of heart transplantation and devicedverse events. Bleeding requiring transfusion and surgery
ere the most common adverse events (see Miller et al. [18]
or definition) in the study and were primarily observed
ithin the first 30 days of device implantation (Table 3).
troke was observed in 25 (8.9%) patients, with the event
ate greatest in the first 30 days. Ischemic strokes were more
ommon than hemorrhagic strokes. Five of the 15 (33%)
schemic strokes occurred within 48 h. Almost one-half of
he strokes were fatal (10 of 25; 40%). After the first 30
ays, the event rates for ischemic and hemorrhagic stroke
ere 0.05 and 0.03 events per patient year, respectively. Six
nuous-Flow Left Ventricular Assist Device
left ventricular assist device for the first 18 months after device implantation.
left
tation for cardiac recovery.onti
us-flows-flow
explan
(
c
i
p
p
o
p
t
R
(
r
1
o
s
(
S
r
d
p
L
1
CO
V
A
*
2
317JACC Vol. 54, No. 4, 2009 Pagani et al.
July 21, 2009:312–21 Continuous-Flow LVAD2%) additional patients had transient ischemic attacks that
ompletely reversed. Other nonstroke neurologic events,
ncluding seizures and confusion, were observed in 15 (5%)
haracteristics of Patients Alive Withngoing Devi e Support as of June 2008 (n  42)Table 2 Characteristic of Patien s Alive WithOngoing Device Support as of June 2008 (n  42)
Duration of LVAD support (yrs) 1.6 (1.3–3.1)
Age 51 (15–70)
Men/women 26 (62)/16 (38)
Listed for cardiac transplantation 30 (71.4)
Not listed for cardiac transplantation 12 (28.6)
Reasons not listed
Irreversible medical condition 3
Noncompliance 3
Obesity 2
Elevated panel reactive antibody screen 2
Preference to stay on device 1
Insurance 1
alues are expressed as median (range) or n (%).
LVAD  left ventricular assist device.
dverse Events (n  281)Table 3 Adverse Events (n  281)
Overall
Cumulative Support Duration (Patient-Years) 181.8
Adverse Event
Patients With
Event, n (%)
No. of
Events
Bleeding
Requiring surgery 72 (26) 82
Requiring 2 U PRBC only 148 (53) 303
Ventricular arrhythmias† 56 (20) 72
Infection
Local nondevice-related infection 84 (30) 155
Sepsis 49 (17) 64
Percutaneous lead infection 41 (14) 56
Pump pocket infection 5 (2) 5
Respiratory failure 72 (26) 88
Renal failure 30 (11) 31
Right heart failure
Need for RVAD 17 (6) 17
Need for extended inotropic support‡ 36 (13) 37
Stroke
Ischemic 15 (5) 16
Hemorrhagic 9 (3) 9
Spinal cord infarct 1 (1) 1
TIA 6 (2) 7
Psychological 16 (6) 18
Other neurological 15 (5) 17
Peripheral non-neurologic TE 18 (6) 25
Device replacement 12 (4) 12
Primary device thrombosis¶ 4 (1) 4
Complications of surgical implantation# 3 (1) 3
Percutaneous lead wire damage 4 (1) 4
Lead and pump pocket infection 1 (0.4) 1
Hemolysis 11 (4) 11
Hepatic dysfunction 7 (2) 7
Events/patient-year. †Requiring cardioversion or defibrillation. ‡Longer than 14 days or starting
4, 56, 123. #Surgical pledget trapped in pump (day 1), temporary RVAD caused kink in LVAD outflow g
HM2  HeartMate II; LVAD  left ventricular assist device; PRBC  packed red blood cells; RVAD  riatients. Psychological symptoms developed in 16 (6%)
atients. Localized infection not related to the device
ccurred in 84 (30%) patients. Infection associated with the
ercutaneous lead was observed in 41 (14%) patients, and
here were 5 (2%) pre-peritoneal pump pocket infections.
espiratory and renal failure occurred in 72 (26%) and 30
11%) patients, respectively. Thirty-six (13%) patients had
ight heart failure requiring inotrope support for more than
4 days. Of the 53 (19%) patients that developed post-
perative right heart failure, survival with continued LVAD
upport at 18 months was 62  8%. Twenty-six of these 53
49%) patients with right heart failure received a transplant.
eventeen (6%) patients received temporary support with
ight ventricular assist devices (median time of support 11.5
ays; range 0 to 148 days). The median duration of
ost-operative inotrope support was 9 days.
A total of 11 (4%) patients underwent 12 HeartMate II
VAD replacements for either device thrombosis (n  4;
.4%) (2 of whom subsequently died), surgical complica-
0–30 Days >30 Days
21.7 160.2
Patients
With Event
No. of
Events
Event
Rate*
Patients
With Event
No. of
Events
Event
Rate*
67 72 3.32 10 10 0.06
128 190 8.76 54 111 0.69
37 41 1.89 23 31 0.19
64 78 3.59 46 78 0.49
26 27 1.24 27 37 0.23
2 2 0.09 39 54 0.34
1 1 0.05 4 4 0.02
61 69 3.18 16 19 0.12
24 24 1.11 7 7 0.04
16 16 0.74 1 1 0.01
28 29 1.34 8 8 0.05
8§ 8 0.37 7 8 0.05
4 4 0.18 5 5 0.03
0 0 0.00 1 1 0.01
3 3 0.14 4 4 0.02
13 13 0.60 3 5 0.03
4 4 0.18 11 13 0.08
16 22 1.02 3 3 0.02
4 4 0.18 8 8 0.05
2 2 0.09 2 2 0.01
2 2 0.09 1 1 0.01
0 0 0.00 4 4 0.03
0 0 0.00 1 1 0.01
6 6 0.28 5 5 0.03
4 4 0.18 3 3 0.02
y 14. §Five events within day 0–2. Replaced with HM2 (n  9) or other LVADs (n  3). ¶Days 0,Event
Rate*
0.45
1.67
0.40
0.85
0.35
0.31
0.03
0.48
0.17
0.09
0.20
0.09
0.05
0.01
0.04
0.10
0.09
0.14
0.07
0.02
0.02
0.02
0.01
0.06
0.04
after da
raft (day 15), or malposition of inflow cannula (day 31).
ght ventricular assist device; TE  thromboembolic event; TIA  transient ischemic attack.
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Continuous-Flow LVAD July 21, 2009:312–21ions at the time of LVAD implantation (n  3; 1.1%),
ercutaneous lead wire damage (n  4; 1.4%), or for
evelopment of device infection (n  1; 0.3%). One patient
ad 2 of the pump replacements (thrombosis and infection).
f the 12 pump replacements, 9 (75%) were replaced with
nother HeartMate II LVAD, and the patients continued
n the study, and 3 (25%) were replaced with another type of
VAD device, and the patients were withdrawn from the
tudy. There were no failures of the mechanical pumping
echanism. The median time to pump replacement was
06 days (range 0 to 672 days). The freedom from major
evice malfunction resulting in death (n  4) or device
eplacement for all causes (malfunction, thrombosis, or
nfection; 9 without deaths) was 96% (95% CI: 95% to 99%)
t 6 months, 93% (95% CI: 90% to 98%) at 1 year, and 92%
95% CI: 88% to 97%) at 18 months (Fig. 4).
Fifty-nine percent of patients (165 of 281) required 368
perations or procedures after device implantation. The
ajority of these occurred within 30 days of device implan-
ation (245 of 368; 67%), and most were required for
e-explorations or sternal closures for bleeding complica-
ions (177 of 245; 72%) followed by temporary RVAD
nsertion or removal (n  18; 7%), tracheostomy (n  12;
%), implantable cardioverter defibrillator insertion or re-
lacement (n  9; 4%), infection (n  7; 3%); pump
eplacement (n 4; 2%), and various other cardiac (n 15;
%) and noncardiac (n  3; 1%) procedures. After 30 days,
he most frequent indication for reoperation was for infec-
ion complications (49 of 123; 40%), bleeding (n 19; 9%),
ump replacement (n  8; 7%), RVAD insertion or
emoval (n  3; 2%), implantable cardioverter defibrillators
n  5; 4%), and various other noncardiac (n  24; 20%)
nd cardiac procedures (n  14; 11%).
Figure 4 Kaplan-Meier Analysis of the Freedom From Major Dev
Analysis of freedom from major device malfunction was defined as the freedom fro
as the result of major device malfunction or need for device replacement for all caunctional assessment, quality of life, and end-organ
unction. Functional assessment with 6-min walk and
YHA functional classification were performed for patients
emaining on device support up to 6 months (Table 4). Of
09 patients with paired values at baseline and at 6 months,
nly 14 of 109 (13%) were able to perform a 6-min walk test
t baseline, compared with 97 (89%) patients after 6 months
f support, and there was a significant improvement in
istance walked between baseline and 6 months.
Additionally, NYHA functional classification improved
rom 3.9  0.3 at baseline (with 0% of patients in NYHA
unctional class I or II) to 1.8  0.7 at 6 months (with 83%
n functional class I or II). Quality of life assessed by both
innesota Living With Heart Failure and the Kansas City
ardiomyopathy Questionnaire was significantly improved
t 6 months compared with baseline (Table 4), with mean
cores improving over 25 U, or 41% and 75%, respectively.
epatic (total bilirubin, serum aspartate aminotransami-
ase, and serum alanine aminotransaminase) and renal
blood urea nitrogen) function significantly improved from
aseline to 6 months, but changes in serum creatinine were
ot statistically significant.
iscussion
ontinuous-flow rotary pumps represent a novel design
oncept for LVADs. Findings from this study have vali-
ated the efficacy and safety profile of this design for
atients awaiting transplantation. At 18 months after
VAD implantation, a majority of patients (79%) under-
ent transplantation, had cardiac recovery, or remained
live with ongoing LVAD support. Of the patients remain-
ng alive with ongoing LVAD support, the majority were
alfunction
th
ncluding device malfunction, thrombosis, or infection.ice M
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July 21, 2009:312–21 Continuous-Flow LVADctively listed for transplant, obtained satisfactory renal
nd hepatic function and functional status, and were free
rom significant neurological injury. For patients that
eceived a transplant, 1-year survival after transplant
urvival was similar (86% at 1 year) to that reported for
ransplant recipients by the Scientific Registry of Trans-
lant Recipients (1). These data confirm the feasibility of
xtended LVAD support with a continuous-flow LVAD
nd importantly provide support for evaluating this
echnology for permanent MCS as an alternative to
ransplantation.
Major adverse events and deaths were associated with
VAD implantation (Table 3). Most deaths occurred
ithin the first 3 months and were attributable to stroke,
nfection, or multiorgan failure. The skewed distribution of
ortality and morbidity events early after implantation
uggests that the acuity of patient illness contributes signif-
cantly to early deaths and complications. Improvements in
atient selection, timing of LVAD implantation, and im-
rovements in device technology should lead to improve-
ents in outcomes. The refinement of risk assessment
cores for patients being evaluated for LVAD therapy will
ssist in defining optimal patient selection and timing of
VAD intervention (19,20). Multivariate analyses have
hown the importance of pre-existing liver and renal dys-
unction, coagulation abnormalities, and lower serum albu-
in as risk factors that can identify patients who may be too
ll for LVAD surgery (19).
There have been no randomized comparisons of implant-
ble LVAD therapy with optimal medical management in
atients awaiting transplantation because of the perceived
enefits of LVAD therapy in patients at imminent risk of
unctional Status, Quality of Life, and End-Organ Function for PatieTable 4 Functional Status, Quality of Life, and End-Organ Funct
Parameter Baseline
Blood chemistry
Serum sodium (mmol/l) 134.1 5.0
Blood urea nitrogen (mg/dl) 28.0 15.2
Serum creatinine (mg/dl) 1.4 0.5
ALT (IU/l)† 108 327
AST (IU/l)† 93 295
Total bilirubin (mg/dl) 1.3 0.9
INR 1.3 0.5
Functional status
NYHA functional class 3.9 0.3
Class I or II (%) 0
6-min walk distance (m)
Patients able to walk at baseline 201 140
Unable to walk at baseline 0 0
Percent of patients able to walk 13
Quality of life
MLWHF 69.4 23.3
KCCQ¶ 35.8 21.4
Paired t test except where indicated. †See Table 2. ‡McNemar’s test. §12 patients were unable to
ndicate better quality of life.
INR  international normalized ratio; KCCQ  Kansas City Cardiomyopathy Score; MLWHF  Minneath and the potential ethical issues of withholding life- paving therapy. Further, there have been no randomized
omparisons of different types of implantable LVAD de-
igns in this population. Data pertaining to the efficacy and
afety profile of a continuous-flow, rotary pump from this
tudy can be placed in perspective when compared histori-
ally with previous FDA-approved clinical studies investi-
ating the use of devices with pulsatile design for patients
ndergoing transplantation.
In these studies, which evaluated 500 patients during a
0-year period, overall survival to transplantation or survival
n LVAD support at 6 months was approximately 70% with
n average support duration typically of 1 to 3 months and
as a consistent finding in each of the clinical studies
2,6,8,21). In a comparison with devices with pulsatile
esign, the continuous-flow, rotary pump demonstrated at
east equal efficacy with regard to hemodynamic support,
bility to improve renal and hepatic function, rates of
ransplantation, and overall patient survival but typically
ver longer durations of support compared with earlier
tudies with pulsatile devices. Actuarial survival on LVAD
upport for patients in this study was 73% at 1 year and
2% at 18 months and appeared superior to survival
bserved during pump support with a pulsatile device
53% at 1 year) (2).
Importantly, significantly fewer deaths were observed
uring late follow-up (6 to 18 months) in the present study,
uggesting that the incidence of major events contributing
o deaths such as stroke, infection, and device malfunction
ere lower with the new design. This late reduction in
eaths has not been previously observed with pulsatile
umps for either BTT (2) or destination therapy (3) and
uggests that refinements in device technology have im-
ith Paired Data at Baseline and at 6 Monthsor Patients With Paired Data at Baseline and at 6 Months
6 Months n p Value*
139.3 3.1 130 0.001
20.3 9.0 130 0.001
1.3 0.7 130 0.119
28 15 128 0.006
34 16 128 0.026
0.8 0.4 127 0.001
2.1 0.9 127 0.001
1.8 0.7 110 0.001
83 110 0.001‡
368 125 14 0.001
326 232 95 0.001
89§ 109 0.001‡
40.7 24.6 92 0.001
62.5 22.6 90 0.001
t baseline or at 6 months. Lower values indicate better quality life. ¶Overall score; greater values
iving With Heart Failure; NYHA  New York Heart Association; other abbreviations as in Table 1.nts Wion f
walk aroved late outcomes. Importantly, excellent late survival on
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Continuous-Flow LVAD July 21, 2009:312–21VAD support (12 to 18 months) was maintained in the
bsence of continuing high rates of attrition to transplan-
ation (Fig. 2), suggesting that significant device complica-
ions requiring urgent transplantation were not prevalent.
The rates of major adverse events appear less for
ontinuous-flow rotary pumps when compared with de-
ices with pulsatile design when comparing rates of
dverse events with similar definitions to historical trials
2). The adverse event rates (in events per patient-year) of
leeding requiring surgery (0.45 vs. 1.47), percutaneous
ead infection (0.26 vs. 3.49), stroke (0.14 vs. 0.44),
onstroke neurological events (0.09 vs. 0.67), and right
eart failure requiring a right ventricular assist device
0.09 vs. 0.30) were significantly less in this current study
ompared with those observed during clinical evaluation
f a pulsatile pump, respectively (2). This comparison is
istorical in nature, and differences in rates of adverse
vents may have been influenced by differences in acuity
f patient illness or improvements in patient management
ver time. However, these improvements are consistent,
t least in part, with improvements in LVAD technology.
Durability and reliability of LVAD design are among the
ost significant features for extended use of MCS devices.
evice replacements in this study were relatively infrequent
espite a cumulative support duration of approximately 180
ears. When device replacement was required, it was largely
or device thrombosis and infection. No mechanical failures
f the pumping mechanism were observed, although there
as damage to wires in the percutaneous leads and 2 deaths
rom problems with grafts and connectors.
Recently, a safety advisory regarding the potential for
ear and fatigue of the percutaneous lead to occur over time
as released by Thoratec Corporation. The advisory pro-
ided an estimate of the probability of the need for pump
eplacement due to percutaneous lead damage to be 1.3% at
2 months, 6.5% at 24 months, and 11.4% at 36 months
nd also noted percutaneous lead care instructions for
atients and caregivers as well as methods to diagnose
linically-relevant wear and fatigue (22). As patients with
VADs become more active and are supported for longer
urations, design improvements are being made to improve
he durability of the percutaneous lead, and modular designs
re under consideration that will permit external exchange
f the percutaneous lead in the event of a lead fracture
ithout the need for pump exchange.
The absence of mechanical failures of the pumping
echanism is very encouraging in the prospect of long-term
herapy for patients with advanced heart failure. Device
xchange is a significant cause of morbidity and mortality
11,12). Data from the present study with a continuous-flow
otary pump demonstrate an important trend toward a low
ate of device replacement required from all causes at 18
onths. These data suggest that small durable devices can
ead to a reduction in infectious and mechanical pump
omplications and support the concept and feasibility of
xtended pump support. wThe use of continuous-flow rotary pumps has raised a
umber of concerns. Continuous-flow rotary pumps signif-
cantly reduce but do not eliminate the normal pressure
mplitude associated with the native circulation that may
nfluence long-term organ function. This initial concern has
ow been refuted by longer-term follow-up from this
resent study that has demonstrated preservation of organ
unction (23). Continuous-flow rotary pumps are currently
esigned to operate at fixed rotor speeds that do not
utomatically adjust to changes in left ventricular pre-load.
re-load changes could limit the capacity of the pump
utput and patient exercise capacity or alternatively might
esult in excessive flow in low filling conditions associated
ith left ventricular collapse and ventricular arrhythmias.
owever, recent reports have suggested that the hydrody-
amic characteristics of the continuous-flow rotary pump
sed in this clinical study allow flow to increase during
xercise and appear to have no or insignificant limitations in
atient exercise performance compared with pulsatile
umps (24).
Additionally, although the risk of pump thrombosis and
hromboembolism (particularly stroke) is low, it has not
een eliminated with the new pump design. Current man-
gement strategies for continuous-flow devices require long-
erm antithrombotic therapy with warfarin, thereby increas-
ng the patient’s risk of hemorrhagic events. The optimum
evel of anticoagulation to minimize both thromobembolic
nd hemorrhagic risks has not been determined from this
resent study because there was variability in the anticoag-
lation management among the participating centers. Al-
hough the smaller percutaneous lead in the continuous-
ow device has appeared to reduce the rates of device-
ssociated infection, infection remains a potential concern.
dditional follow-up is needed to establish the durability
nd reliability of the pump mechanism over the longer term
18 months).
tudy limitations. The study was a nonrandomized com-
arison. Thus, direct comparisons of the current study of a
ontinuous-flow rotary pump to medical therapy or to other
tudies of pulsatile- or continuous-flow pump designs can-
ot be performed. Second, the study was performed in a
TT population. There was a significant attrition of pa-
ients to transplantation (50%) by 1 year. Although this was
he intent of the study, attrition of patients impacts the
nterpretation of data obtained from the patients remaining
n device support as a result of the potential bias from
iving priority to transplantation of patients experiencing
he least benefit from the device.
onclusions
continuous-flow rotary pump LVAD with axial design
rovides safe, reliable, and effective hemodynamic support
n patients awaiting transplantation with improved quality
f life and functional capacity. Furthermore, LVAD therapy
ith continuous-flow rotary pumps with extended support
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July 21, 2009:312–21 Continuous-Flow LVADs associated with a very low rate of device malfunction or
nfection requiring device exchange. Continuous-flow ro-
ary pumps provide a superior alternative to pumps with a
ulsatile design in patients awaiting transplantation.
eprint requests and correspondence to: Dr. Francis D. Pagani,
ection of Cardiac Surgery, University of Michigan Health Sys-
em, Cardiovascular Center, Room 5161, 1500 East Medical
enter Drive, SPC#5864, Ann Arbor, Michigan 48109. E-mail:
pagani@umich.edu.
EFERENCES
1. Mulligan MS, Shearon TH, Weill D, Pagani FD, Moore J, Murray S.
Heart and lung transplantation in the United States, 1997–2006. Am J
Transplant 2008;8:977–87.
2. Frazier OH, Rose EA, Oz MC, et al. Multicenter clinical evaluation
of the HeartMate vented electric left ventricular assist system in
patients awaiting heart transplantation. J Thorac Cardiovasc Surg
2001;122:1186–95.
3. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left
ventricular assist device for end-stage heart failure. N Eng J Med
2001;345:1435–43.
4. Park SJ, Tector A, Piccioni W, et al. Left ventricular assist devices as
destination therapy: a new look at survival. J Thorac Cardiovasc Surg
2005;129:9–17.
5. Joyce LD, Noon GP, Joyce DL, et al. Mechanical circulatory
support—a historical review. ASAIO J 2004;50:x–xii.
6. Slaughter MS, Tsui SS, El-Banayosy A, et al. Results of a multicenter
clinical trial with the Thoratec Implantable Ventricular Assist Device.
J Thorac Cardiovasc Surg 2007;133:1573–80.
7. El-Banayosy A, Arusoglu L, Kizner L, et al. Novacor left ventricular
assist system versus HeartMate vented electric left ventricular assist
system as a long-term mechanical circulatory support device in
bridging patients: a prospective study. J Thorac Cardiovasc Surg
2000;119:581–7.
8. Farrar DJ, Hill JD, Pennington DG, et al. Preoperative and postop-
erative comparison of patients with univentricular and biventricular
support with the Thoratec ventricular assist device as a bridge to heart
transplantation. J Thorac Cardiovasc Surg 1997;113:202–9.
9. Baughman KL, Jarcho JA. Bridge to life—cardiac mechanical support.
N Engl J Med 2007;357:846–9.
0. Dowling RD, Park SJ, Pagani FD, et al. HeartMate VE LVAS design
enhancements and its impact on device reliability. Eur J Cardiothorac
Surg 2004;25:958–63. t1. Pagani FD, Long JW, Dembitsky WP, et al. Improved mechanical
reliability of the HeartMate XVE Left Ventricular Assist System. Ann
Thorac Surg 2006,82:1413–9.
2. Dembitsky WP, Tector AJ, Park S, et al. Left ventricular assist device
performance with long term circulatory support: lessons from the
REMATCH trial. Ann Thorac Surg 2004;78:2123–30.
3. Takatani S. Progress of rotary blood pumps: Presidential Address,
International Society for Rotary Blood Pumps 2006, Leuven, Belgium.
Artif Organs 2007;31:329–344.
4. Hoshi H, Shinshi T, Takatani S. Third-generation blood pumps with
mechanical noncontact magnetic bearings. Artif Organs 2006;30:
324–38.
5. Goldstein DJ, Zucker M, Arroyo L, et al. Safety and feasibility trial of
the MicroMed DeBakey ventricular assist device as a bridge to
transplantation. J Am Coll Cardiol 2005;45:962–3.
6. Esmore D, Spratt P, Larbalestier R, et al. VentrAssist left ventricular
assist device: clinical trial results and clinical development plan update.
Eur J Cardiothorac Surg 2007;32:735–44.
7. Göttel P, Hetzer R, Schmid C, et al. Clinical results of the first 99
patients with the axial flow pump INCOR (abstr). J Heart Lung
Transplant 2005;24 Suppl 1:S57.
8. Miller LW, Pagani FD, Russell SD, et al. Use of a continuous-flow
device in patients awaiting heart transplantation. N Engl J Med
2007;357:885–96.
9. Lietz K, Long JW, Kfoury AG, et al. Outcomes of left ventricular
assist device implantation as destination therapy in the post-
REMATCH era: implications for patient selection. Circulation 2007;
116:497–505.
0. Matthews JC, Koelling TM, Pagani FD, Aaronson KD. The right
ventricular failure risk score a pre-operative tool for assessing the risk
of right ventricular failure in left ventricular assist device candidates.
J Am Coll Cardiol 2008;51:2163–72.
1. Frazier OH, Rose EA, McCarthy P, et al. Improved mortality and
rehabilitation of transplant candidates treated with a long-term im-
plantable left ventricular assist system. Ann Surg 1995;222:327–36.
2. United States Food and Drug Administration, MedWatch, Food and
Drug Administration Safety Information and Adverse Event Report-
ing Program, 2008 Safety Alerts for Human Medical Products (Drugs,
Biologics, Medical Devices, Special Nutrionals, and Cosmetics). Re-
ported October 2008. Available at: http://www.fda.gov/medwAtch/
safety/2008/safety08.htm#HeartMate. Accessed January 10, 2009.
3. Radovancevic B, Vrtovec B, de Kort E, et al. End-organ function in
patients on long-term circulatory support with continuous- or
pulsatile-flow assist devices. J Heart Lung Transplant 2007;26:
815– 8.
4. Haft J, Armstrong W, Dyke DB, et al. Hemodynamic and exercise
performance with pulsatile and continuous flow left ventricular assist
devices. Circulation 2007;116 Suppl I:I8–15.
ey Words: heart failure y left ventricular assist device y heart
ransplantation.
